8 active not recruiting, 4 recruiting, 2 suspended, 1 terminated. 15 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Active not recruiting 8, Recruiting 4, Suspended 2, Terminated 1 |
| Phase 2 | 5 | Active not recruiting 3, Recruiting 1, Suspended 1 |
Follow SB27: new trials by email Literature Review of SB27 trials Research Report on SB27
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Recruiting | City of Hope Medical Center | 6 | 2026-09-01 | 2026-10-19 |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 27 | 2025-05-05 | 2026-09-21 |
| A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy SB27, EU sourced Keytruda, US sourced Keytruda - Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA | Phase 1 | Active not recruiting | Samsung Bioepis Co., Ltd. | 163 | 2024-01-16 | 2026-05-05 |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Suspended | National Cancer Institute (NCI) | 32 | 2023-09-25 | 2026-07-31 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2023-05-18 | 2026-09-30 |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2022-07-27 | 2026-11-10 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-09-21 |
| Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2019-11-18 | 2026-07-31 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab - Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2018-10-04 | 2026-10-15 |
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 36 | 2018-05-30 | 2026-07-31 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 59 | 2015-04-08 | 2026-10-07 |
Brain Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Familial ependymoma (1)
National Cancer Institute (NCI) (11) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · Samsung Bioepis Co., Ltd. (1)
United States (14) · Canada (4) · Poland (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1)
Aaron S Mansfield (1) · Ana C Garrido-Castro (1) · Anish Thomas (1) · Bently Doonan, MD, MS (1) · Diwakar Davar (1) · Eugene I Hwang (1) · Frank S Hodi (1) · Liza C Villaruz (1) · Maha H Hussain (1) · Matthew D Galsky (1) · Roberto A Leon-Ferre (1) · Rosa Nadal Rios, MD, PhD (1) · Sagus Sampath (1) · Yvonne M Mowery (1)
PMID 35264434, PMID 38236249, PMID 41206673
UM1CA186709 (4), UM1CA186690 (3), P30CA033572 (1), P30CA060553 (1), U01CA062490 (1), UM1CA081457 (1), UM1CA186644 (1), UM1CA186686 (1)